MSD Brazil
Brazil subsidiary of a global biopharmaceutical company focused on discovery, development, registration and commercialization of medicines and vaccines. Operates clinical trial programs (including global Phase 3 studies), medical information and pharmacovigilance channels, regulatory interactions with ANVISA, and public-health campaigns and real-world evidence generation in Brazil.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Medicines and vaccines across multiple therapeutic areas
Commercialization and local regulatory maintenance of therapeutics and vaccines in oncology, infectious disease, vaccines, diabetes, anesthesia and rare diseases.
Medicines and vaccines across multiple therapeutic areas
Commercialization and local regulatory maintenance of therapeutics and vaccines in oncology, infectious disease, vaccines, diabetes, anesthesia and rare diseases.
Services
Planning and operational delivery of multicenter clinical trials including site network coordination, patient recruitment, monitoring and data collection.
Centralized channels for medical inquiries, adverse event reporting and product quality complaints, with case processing for regulatory reporting.
Preparation and submission of dossiers and notifications to national regulators, and coordination of product availability communications.
Design and implementation of awareness campaigns and educational activities to increase vaccination and screening uptake.
Planning and operational delivery of multicenter clinical trials including site network coordination, patient recruitment, monitoring and data collection.
Centralized channels for medical inquiries, adverse event reporting and product quality complaints, with case processing for regulatory reporting.
Preparation and submission of dossiers and notifications to national regulators, and coordination of product availability communications.
Design and implementation of awareness campaigns and educational activities to increase vaccination and screening uptake.
Expertise Areas
- Clinical trial management (Phase 1–3)
- Oncology drug development
- Vaccine development and immunization programs
- Pharmacovigilance and medical safety
Key Technologies
- Randomized double‑blind placebo‑controlled trial methodology
- PD‑1 checkpoint inhibitor immunotherapy
- Vaccine technologies (recombinant, conjugate, polysaccharide)
- Antibody‑drug conjugates
News & Updates
Regulatory approval based on a Phase 3 randomized trial showing improved recurrence‑free survival in resected melanoma.
Approval of a novel biologic class for pulmonary arterial hypertension supported by positive Phase 3 STELLAR study results.
ANVISA approval of an immunotherapy plus antibody‑drug conjugate combination as a first‑line option for advanced urothelial carcinoma.
Retrospective analysis of treatment patterns and health‑resource utilization to inform public policy.
Regulatory approval based on a Phase 3 randomized trial showing improved recurrence‑free survival in resected melanoma.
Approval of a novel biologic class for pulmonary arterial hypertension supported by positive Phase 3 STELLAR study results.
ANVISA approval of an immunotherapy plus antibody‑drug conjugate combination as a first‑line option for advanced urothelial carcinoma.
Retrospective analysis of treatment patterns and health‑resource utilization to inform public policy.